Title: Hypothyroidism does not lead to worse prognosis in COVID-19: findings from the Brazilian COVID-19 registry

Authors:

Daniella Nunes Pereira¹ (Pereira DN - dani_nunesp@hotmail.com, 0000-0002-3124-9322)
 Leticia Ferreira Gontijo Silveira, MD, PhD² (Silveira LFG- leticiafgs@ufmg.br . 0000-0002-0053-9167)
 Milena Maria Moreira Guimarães, MD, PhD² (Guimarães MMM - milenamg2@gmail.com 0000-0003-3651-185X)
 Carísi Anne Polanczyk, PhD³ (Polanczyk CA- carisi.anne@gmail.com 0000-0002-2447-2577)
 Aline Gabrielle Sousa Nunes, MD⁴ (Nunes AGS- alinegsn89@yahoo.com.br 0000-0001-8036-0871)
 André Soares de Moura Costa, MD, MSc⁵ (Costa ASM- andresmc@gmail.com 0000-0002-9153-1186)
 Barbara Lopes Farace, MD⁶ (Farace BL- barbarafarace@gmail.com 0000-0002-6172-1093)
 Christiane Corrêa Rodrigues Cimini⁷ (Cimini CCR- christiane.cimini@gmail.com 0000-0002-1973-1343)
 Cíntia Alcantara de Carvalho, MD⁸ (Carvalho CAC- carvalho.cintiaa@gmail.com 0000-0001-8240-2481)
 Daniela Ponce⁹ (Ponce D- daniela.ponce@unesp.br 0000-0002-6178-6938)
 Eliane Würdig Roesch¹⁰ (Roesch EW- eroesch@hcpa.edu.br 0000-0002-9507-6344)
 Euler Roberto Fernandes Manenti¹¹ (Manenti ERF- eulermanenti@gmail.com 0000-0003-1592-4727)
 Fernanda Barbosa Lucas¹² (Lucas FB- fbl_lucas@yahoo.com.br)
 Fernanda d'Athayde Rodrigues, PhD¹³ (Rodrigues FA- fe.athayde@gmail.com 0000-0001-7368-3592)
 Fernando Anschau, PhD¹⁴ (Anschau F- afernando@ghc.com.br 0000-0002-2657-5406)
 Fernando Graça Aranha¹⁵ (Aranha FG- fgaranha@icloud.com 0000-0001-9173-8892)
 Frederico Bartolazzi¹² (Bartolazzi B- fredlazzi@hotmail.com 0000-0002-9696-4685)
 Giovanna Grunewald Vietta¹⁵ (Vietta GG- ggvietta@gmail.com 0000-0002-0756-3098)
 Guilherme Fagundes Nascimento, MSc¹⁶ (Nascimento GF- guilhermefagundesn@hotmail.com 0000-0001-9064-7067)
 Helena Duani¹⁷ (Duani H- hduani@yahoo.com.br 0000-0001-9345-018X)

Heloisa Reniers Vianna¹⁸ (Vianna HR- hrvianna@hotmail.com 0000-0003-1144-6262)

Henrique Cerqueira Guimarães, PhD¹⁹ (Guimarães HC - hcerqueirag@gmail.com, 0000-0001-6511-7400)

Jamille Hemétrio Salles Martins Costa²⁰ (Costa JHSM- jamillesalles@yahoo.com.br 0000-0002-7577-6060)

Joanna d'Arc Lyra Batista²¹ (Batista JAL- joannalyra@gmail.com 0000-0002-3703-2845)

Joice Coutinho de Alvarenga⁸ (Alvarenga JC- joice-alvarenga@hotmail.com 0000-0003-3536-7112)

José Miguel Chatkin, MD, PhD²² (Chatkin JM- jmchatkin@puccs.br 0000-0002-4343-025X)

Júlia Drumond Parreiras de Moraes²³ (Moraes JDP- juliadrumond_@hotmail.com 0000-0003-1144-6262)

Juliana Machado-Rugolo²⁴ (Machado-Rugolo J- jr.machado@unesp.br 0000-0003-3984-4959)

Karen Brasil Ruschel²⁵ (Ruschel KB- karenbruschel@gmail.com 0000-0002-6362-1889)

Lílian Santos Pinheiro²⁶ (Pinheiro LS- lilian.pinheiro98@hotmail.com 0000-0003-2957-7674)

Luanna Silva Monteiro Menezes²⁷ (Menezes LS- luannasmonteiro@gmail.com 0000-0002-6621-3338)

Luciana Siuves Ferreira Couto²⁷ (Couto LSF- lucianasiuves@gmail.com 0000-0002-7948-222X)

Luciane Kopittke, PhD²⁸ (Kopittke L- kluciane@ghc.com.br 0000-0002-6606-7756)

Luís César de Castro, PhD²⁹ (Castro LC- pharmlucamsc@gmail.com 0000-0003-2379-0167)

Luiz Antônio Nasi³⁰ (Nasi LA- lnasi@terra.com.br 0000-0002-7069-5827)

Máderson Alvares de Souza Cabral³¹ (Cabral MA- madersonalvares@hotmail.com 0000-0001-8556-1998)

Maiara Anschau Floriani³⁰ (Floriani MA- maiara.floriani@hmv.org.br 0000-0002-2981-9445)

Maíra Dias Souza³² (Souza MD- mairadiassouza@gmail.com 0000-0003-3546-4000)

Marcelo Carneiro³³ (Carneiro M- marceloc@unisc.br 0000-0003-3603-1987)

Maria Aparecida Camargos Bicalho³⁴ (Bicalho MAC- macbicalho@gmail.com 0000-0001-6298-9377)

Mariana Frizzo de Godoy³⁵ (Godoy MF- mfdegodoy@gmail.com 0000-0002-6631-8826)

Matheus Carvalho Alves Nogueira⁵ (Nogueira MCA- mathnogueira42@gmail.com 0000-0002-0241-9046)

Milton Henriques Guimarães Júnior²⁰ (Júnior MHG- miltonhenriques@yahoo.com.br 0000-0002-2127-8015)

Natália da Cunha Severino Sampaio³⁶ (Sampaio NCS- natsamster@gmail.com 0000-0002-5799-8006)

Neimy Ramos de Oliveira³⁶ (Oliveira NR- neimyramos@gmail.com 0000-0001-5408-9459)

Pedro Ledic Assaf³⁷ (Assaf PL- pedro.ledic@hmdcc.com.br 0000-0002-8419-5719)

Renan Goulart Finger²¹ (Finger RG- renanfinger@yahoo.com.br 0000-0002-5569-7787)

Roberta Xavier Campos³⁴ (Campos RX- xaviercampos.roberta@gmail.com 0000-0002-2963-8994)

Rochele Mosmann Menezes³³ (Menezes RM- rochelemenezes@unisc.br 0000-0002-1548-1607)

Saionara Cristina Francisco³⁷ (Francisco SC- saionaracf@gmail.com 0000-0002-9655-6294)

Samuel Penchel Alvarenga³⁸ (Alvarenga SP- samuelpenchel@gmail.com 0000-0002-1889-3455)

Silvana Mangeon Mereilles Guimarães³⁹ (Guimarães SMM- smangeon@gmail.com 0000-0003-4782-5440)

Silvia Ferreira Araújo³⁹ (Araújo SF- silviaferreiragastro@gmail.com 0000-0003-4782-5440)

Talita Fischer Oliveira³² (Oliveira TF- talitafischeroliveira@gmail.com 0000-0002-4614-3109)

Thulio Henrique Oliveira Diniz³⁸ (Diniz THO- thuliodinizmed@gmail.com 0000-0003-1798-4643)

Yuri Carlotto Ramires⁴⁰ (Ramires YC- yuri.ramires@gmail.com 0000-0002-0730-8716)

Evelin Paola de Almeida Cenci⁴¹ (Cenci EPA-assistencial6_hu@centrodepesquisaclinica.com.br 0000-0001-8548-9279)

Thainara Conceição de Oliveira⁴¹ (Oliveira TC- thainarastaehler@hotmail.com 0000-0002-1248-2305)

Alexandre Vargas Schwarzbald⁴² (Schwarzbald AV- alexvspoa@gmail.com 0000-0002-5535-6288)

Patricia Klarmann Ziegelmann⁴³ (Ziegelmann PK- patriciakz99@gmail.com 0000-0002-2851-2011)

Roberta Pozza⁴³ (Pozza R- robertapozza@tacchini.com.br 0000-0003-1733-6398)

Magda Carvalho Pires PhD⁴⁴ (Pires MC – magda@est.ufmg.br, 0000-0003-3312-4002)

Milena Soriano Marcolino MD, MSc, PhD⁴⁵ (Marcolino MS - milenamarc@ufmg.br, 0000-0003-4278-3771)

- ¹ Undergraduate Medical Student. Universidade Federal de Minas Gerais. Avenida Professor Alfredo Balena, 190, Belo Horizonte, Brazil.
- ² Endocrinology Unit, Department of Internal Medicine, Faculdade de Medicina da Universidade Federal de Minas Gerais. Avenida Professor Alfredo Balena 190, Belo Horizonte, Brazil.
- ³ Professor and Physician. Internal Medicine Department. Universidade Federal do Rio Grande do Sul. Coordinator of the Institute for Health Technology Assessment (IATS/CNPq). Rua Ramiro Barcelos, 2359. Prédio 21 | Sala 507, Porto Alegre, Brazil.
- ⁴ Physician. Hospital Unimed-BH. Av do Contorno, 3097, Belo Horizonte, Brazil.
- ⁵ Hospitais da Rede Mater Dei, Belo Horizonte, Brasil.
- ⁶ Internal Medicine Resident. Hospital Risoleta Tolentino Neves. Rua das Gabirobas, 01, Belo Horizonte, Brazil.
- ⁷ Physician. Hospital Santa Rosália, Teófilo Otoni, Brazil.
- ⁸ Hospital João XXIII. Av. Professor Alfredo Balena, 400, Belo Horizonte, Brazil.
- ⁹ Physician. Hospital das Clínicas da Faculdade de Medicina de Botucatu. Botucatu, Brazil.
- ¹⁰ Hospital de Clínicas de Porto Alegre. Av. Ramiro Barcellos, 2350, Porto Alegre, Brazil.
- ¹¹ Hospital Mãe de Deus, Porto Alegre, Brazil.
- ¹² Hospital Santo Antônio, Curvelo, Brasil.
- ¹³ Pharmaceutical. Hospital de Clínicas de Porto Alegre. Av. Ramiro Barcellos, 2350, Porto Alegre, Brazil.
- ¹⁴ Coordinator of the Research Sector of Grupo Hospitalar Conceição. Professor of the Graduation Program on Evaluation and Production of Technologies for the Brazilian National Health System, Hospital Nossa Senhora da Conceição and Hospital Cristo Redentor. Av. Francisco Trein, 326, Porto Alegre, Brazil.
- ¹⁵ Hospital SOS Córdio, Florianópolis, Brasil.
- ¹⁶ Emergency and Internal Medicine Physician, Hospital Unimed BH. Av. do Contorno, 3097, Belo Horizonte, Brazil.
- ¹⁷ Professor and Infectious Diseases Physician. Internal Medicine Department. University Hospital, Universidade Federal de Minas Gerais. Av. Prof Alfredo Balena, 110, Belo Horizonte, Brazil.
- ¹⁸ Nephrologist. Hospital Universitário Ciências Médicas, Belo Horizonte, Brazil.
- ¹⁹ Hospital Risoleta Tolentino Neves. Rua das Gabirobas, 01, Belo Horizonte, Brazil.

- ²⁰ Hospital Márcio Cunha, Ipatinga, Brasil.
- ²¹ Professor at Federal University of Fronteira Sul, Chapecó, SC, Brazil. Hospital Regional do Oeste, Chapecó, Santa Catarina, Brazil.
- ²² PhD, Departamento de Pneumologia, Faculdade de Medicina, Universidade Católica do Rio Grande do Sul (RGS), Porto Alegre, Brasil. Hospital São Lucas PUCRS, Porto Alegre, Brasil.
- ²³ Physician. Hospital Universitário Ciências Médicas, Belo Horizonte, Brazil.
- ²⁴ Pharmaceutical. Hospital das Clínicas da Faculdade de Medicina de Botucatu, Botucatu, São Paulo, Brazil.
- ²⁵ PhD. Hospital Mãe de Deus, Hospital Universitário de Canoas, Universidade Federal do Rio Grande do Sul e Instituto de Avaliação de Tecnologia em Saúde (IATS/CNPQ), Porto Alegre, Brasil. E-mail: karenbruschel@gmail.com. ORCID: 0000-0002-6362-1889. ¹⁴ MD. Rede Mater Dei de Saúde, Belo Horizonte, Brasil.
- ²⁶ Undergraduate Medical Student. Universidade Federal dos Vales do Jequitinhonha e Mucuri. R. Cruzeiro, 1, Teófilo Otoni, Brazil.
- ²⁷ Hospital Luxemburgo, Belo Horizonte, Brazil.
- ²⁸ Hospital Nossa Senhora da Conceição. Av. Francisco Trein, 326, Porto Alegre, Brazil.
- ²⁹ Clinical Pharmacist - UDM Coordinator of Specialized Assistance Service. Pharmaceutical Assistance Research Center of Vale do Taquari. Av. Rio Branco, 1127, Estrela, Brazil. Hospital Bruno Born. Av. Benjamin Constant, 881, Lajeado, Brazil.
- ³⁰ Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil.
- ³¹ Physician and Master's Student. Medical School, Universidade Federal de Minas Gerais. Avenida Professor Alfredo Balena, 190, sala 246, Belo Horizonte, Brazil.
- ³² Hospital Metropolitano Odilon Behrens, Belo Horizonte, Brazil.
- ³³ Hospital Santa Cruz, Santa Cruz do Sul, Brazil.
- ³⁴ Hospital Julia Kubitschek. Avenida Professor Alfredo Balena 190, Belo Horizonte, Brazil.
- ³⁵ Hospital São Lucas PUCRS, Porto Alegre, Brasil.
- ³⁶ Physician. Hospital Eduardo de Menezes. R. Dr. Cristiano Rezende, 2213, Belo Horizonte, Brazil.
- ³⁷ Physician. Hospital Metropolitano Doutor Célio de Castro. Rua Dona Luiza, 311, Belo Horizonte, Brazil.
- ³⁸ Hospital São João de Deus, Divinópolis, Brazil.
- ³⁹ Hospital Semper. Alameda Ezequiel Dias, 389, Belo Horizonte, Brazil.
- ⁴⁰ Hospital Bruno Born. Av. Benjamin Constant, 881, Lajeado, Brazil.

⁴¹ Hospital Universitário Canoas, Canoas, Rio Grande do Sul, Brazil.

⁴² Hospital Universitário de Santa Maria, Santa Maria, Rio Grande do Sul, Brazil.

⁴³ Hospital Tacchini, Bento Gonçalves, Brasil.

⁴⁴ Associate Professor and Statistician, Department of Statistics, Universidade Federal de Minas Gerais. Av. Presidente Antônio Carlos, 6627, ICEx, sala 4071, Belo Horizonte, Brazil

⁴⁵ Associate Professor and Internal Medicine Physician. Department of Internal Medicine, Medical School; and Telehealth Center, University Hospital, Universidade Federal de Minas Gerais. Avenida Professor Alfredo Balena 190 sala 246, Belo Horizonte, Brazil. Researcher. Institute for Health Technology Assessment (IATS/ CNPq). Rua Ramiro Barcelos, 2359. Prédio 21 | Sala 507, Porto Alegre, Brazil.

Correspondence to:

Milena Soriano Marcolino

University Hospital, Universidade Federal de Minas Gerais

Avenida Professor Alfredo Balena, 110 Room 107. Ala Sul.

Santa Efigênia – Belo Horizonte – MG. Brazil.

CEP 30130-100

Abstract

Background: It is not clear whether previous thyroid diseases influence the course and outcomes of COVID-19. The study aims to compare clinical characteristics and outcomes of COVID-19 patients with and without hypothyroidism.

Methods: The study is a part of a multicentric cohort of patients with confirmed COVID-19 diagnosis, including data collected from 37 hospitals. Matching for age, sex, number of comorbidities and hospital was performed to select the patients without hypothyroidism for the paired analysis.

Results: From 7,762 COVID-19 patients, 526 had previously diagnosed hypothyroidism (50%) and 526 were selected as matched controls. The median age was 70 (interquartile range 59.0-80.0) years-old and 68.3% were females. The prevalence of underlying comorbidities were similar between groups, except for coronary and chronic kidney diseases, that had a higher prevalence in the hypothyroidism group (9.7% vs. 5.7%, $p=0.015$ and 9.9% vs. 4.8%, $p=0.001$, respectively). At hospital presentation, patients with hypothyroidism had a lower frequency of respiratory rate > 24 breaths per minute (36.1% vs 42.0%; $p=0.050$) and need of mechanical ventilation (4.0% vs 7.4%; $p=0.016$). D-dimer levels were slightly lower in hypothyroid patients (2.3 times higher than the reference value vs 2.9 times higher; $p=0.037$). In-hospital management was similar between groups, but hospital length-of-stay (8 vs 9 days; $p=0.029$) and mechanical ventilation requirement (25.4% vs. 33.1%; $p=0.006$) were lower for patients with hypothyroidism. There was a trend of lower in-hospital mortality in patients with hypothyroidism (22.1% vs. 27.0%; $p=0.062$).

Conclusion: In this large Brazilian COVID-19 Registry, patients with hypothyroidism had a lower requirement of mechanical ventilation, and showed a trend of lower in-hospital mortality. Therefore, hypothyroidism does not seem to be associated with a worse prognosis, and should not be considered among the comorbidities that indicate a risk factor for COVID-19 severity.

Keywords: Hypothyroidism; COVID-19; Mortality; Prognosis; Epidemiology

Background

A global health crisis was established with the emergence of the coronavirus disease 19 (COVID-19).¹ It is well known that individuals with some underlying medical conditions, such as cardiovascular diseases, cancer, obesity, diabetes and hypertension, are more likely to develop severe COVID-19, require hospitalization and intensive care, and have higher mortality rates.^{2,3,4} Nevertheless, other conditions such as asthma and Chagas disease surprisingly have not been related to more severe cases of COVID-19.⁵ However, many factors that interfere on COVID-19 clinical characteristics, symptoms and prognosis are still unknown and require further investigation to improve disease prevention and patient management.

It is not clear whether previous thyroid disease influences COVID-19 course.⁶ Previous studies suggested that patients' thyroid status might have a direct impact on the course of COVID-19 due to the effects of thyroid hormone on multiple organs systems, including the cardiovascular and respiratory systems.⁷ Some studies have indeed observed that hypothyroidism may be associated with an increased risk for COVID-19 or a poorer prognosis in patients with the disease.^{8,9} However, these studies are limited due to small sample sizes and lack of comparison with patients without hypothyroidism.

Other studies have found that previous diagnosis of hypothyroidism or other thyroid diseases were not a risk factor for COVID-19 infection and were not associated with poorer outcomes of the disease.^{10,11,12,13} It is well known that critically ill patients with no previous history of thyroid dysfunction usually present alterations in thyroid hormones levels, a situation known as non-thyroidal illness syndrome (NTIS).¹⁴ Patients with NTIS typically present with decreased concentrations of plasma triiodothyronine (T3), low thyroxine (T4), and usually slightly decreased thyroid-stimulating hormone (TSH), which may be variable depending on the phase of the disease.¹⁴ In intensive care units (ICU), patients with conditions such as sepsis, major trauma or burn, and cardiac surgery, among others, NTIS has been associated with disease severity and mortality, without cause-effect association. Rather, NTIS is more likely to be seen as an adaptive mechanism to critical illnesses.^{10,14,15} As we could expect, NTIS has been frequently observed in COVID-19 patients, with the same pattern as in other critical conditions.^{16,17,18}

Literature regarding the association between COVID-19 and previous hypothyroidism is still controversial, results may be biased by the inclusion of NTIS patients, and more studies with larger sample sizes and comparison with non-hypothyroidism patients are still

needed. This study aims to compare the evolution of COVID-19 in patients with previous diagnosis of underlying hypothyroidism to patients without the disease, in order to understand if hypothyroidism is an independent risk-factor in the course of COVID-19.

METHODS

Study design and subjects

This study is a part of the multicentric cohort study Brazilian Covid-19 Registry, which included data from consecutive patients with confirmed COVID-19 diagnosis by RT-PCR or serological tests (IgM) from 37 hospitals.¹⁹ Patients were admitted from March 1st to September 31st, 2020.

For the present analysis, "cases" were patients with a clinical history of previously diagnosed hypothyroidism, on levothyroxine replacement therapy. From 7,762 patients with confirmed COVID-19 diagnosis, 555 (7.15%) had underlying hypothyroidism. Of those, 21 were excluded due to hospital admission for other reasons (not COVID-19), 3 were excluded due to pregnancy and 5 were transferred to other hospitals, with 526 hypothyroid patients remaining eligible for the study (Figure 1). Those patients were admitted in 31 hospitals, located in 15 cities (Belo Horizonte, Betim, Curvelo, Ipatinga, Teófilo Otoni, Divinópolis, Porto Alegre, Bento Gonçalves, Santa Cruz do Sul, Canoas, Santa Maria, Lajeado, Chapecó, Florianópolis and Botucatu) in 4 Brazilian states (Minas Gerais, Rio Grande do Sul, Santa Catarina and São Paulo). Of those, 13 were public, 15 private hospitals and 3 mixed hospitals. In order to compare patient outcomes and disease course, a paired analysis was made with matched controls with no previous history of hypothyroidism.

Figure 1- Flowchart of patients included in the study

This study adheres to the STROBE guidelines (*Strengthening the Reporting of Observational Studies in Epidemiology*²⁰), and it has been conducted by a protocol approved by the National Commission for Research Ethics²¹ (CAAE 30350820.5.1001.0008). Individual informed consent was waived due to the pandemic and to the fact that all data collected was unidentified, gathered through medical records.

Data collection

Data was collected through the analysis of medical records by trained health professionals or undergraduate students (from Medical and Nursing schools) using Research Data Capture (REDCap) tools.²² In the medical records, data collected concerned demographic and clinical characteristics, comorbidities, medication in use prior to admission, COVID-19 symptoms, clinical evaluation at admission, laboratory and radiological exams,

medication used during hospitalization and outcomes. Study protocol and definitions were published elsewhere.²³

Statistical analysis

Statistical analysis was performed using R software (version 4.0.2). To adjust for potential confounding variables, patients who had underlying hypothyroidism were matched to patients who had not underlying hypothyroidism (controls) on the basis of propensity score. Propensity score model was estimated by logistic regression, and included gender, age, number of comorbidities (hypertension, diabetes mellitus, obesity, coronary artery disease, heart failure, atrial fibrillation or flutter, cirrhosis, chronic obstructive pulmonary disease, cancer and previous stroke)⁴ and hospital. Patients from the control group were searched to find those who had the closest propensity score from the hypothyroidism group (within 0.17 standard deviations of the logit of the propensity score, on a scale from 0-1.00), using the MatchIt package in R software.

Categorical data were presented as absolute frequency and proportions, and continuous variables were expressed as medians and interquartile ranges. The Chi-Square and Fisher Exact tests were used to compare the distribution of categorical variables, and the Wilcoxon-Mann-Whitney test for continuous variables. Results were considered statistically significant if the two-tailed P-value was < 0.05.

RESULTS

The study sample comprehended 526 individuals with previous hypothyroidism history and 526 matched controls. The median age was 70 yrs (59-80) and 68.3% were female. Most patients (85.8%) had at least one comorbidity, with the most common being hypertension (72.0%), diabetes mellitus (38.8%), obesity (18.9%) and heart failure (11.2%). In comparison to the controls, patients with underlying hypothyroidism had similar prevalence of comorbidities and unhealthy habits, except for a higher prevalence of coronary disease (9.7% vs. 5.7%, $p=0.015$) and chronic kidney disease (9.9% vs. 4.8%, $p=0.001$) among the hypothyroidism group (Table 1).

Table 1- Demographics and clinical characteristics of the study cohort

	Hypothyroidism N = 526 ¹	Control patients N = 526 ¹	p-value ²
Age (years)	71.0 (60.0, 80.0)	70.0 (59.0, 80.0)	0.659
Female sex	356 (67.7%)	363 (69.0%)	0.643
<i>Cardiovascular diseases</i>			
Hypertension	370 (70.3%)	387 (73.6%)	0.243
Heart failure	65 (12.4%)	53 (10.1%)	0.241
Coronary artery disease	51 (9.7%)	30 (5.7%)	0.015
Atrial fibrillation/flutter	36 (6.8%)	37 (7.0%)	0.903
Stroke	28 (5.3%)	34 (6.5%)	0.432
<i>Respiratory diseases</i>			
COPD	42 (8.0%)	44 (8.4%)	0.822
Asthma	35 (6.7%)	34 (6.5%)	0.901
<i>Metabolic diseases</i>			
Diabetes mellitus	215 (40.9%)	193 (36.7%)	0.164
Obesity (BMI > 30kg/m ²)	94 (17.9%)	95 (18.1%)	0.936
<i>Other conditions</i>			
Chronic kidney disease	52 (9.9%)	25 (4.8%)	0.001
Cancer	29 (5.5%)	38 (7.2%)	0.256
Dementia	16 (3.0%)	11 (2.1%)	0.330
Rheumatological disease	16 (3.0%)	9 (1.7%)	0.157
Cirrhosis	4 (0.8%)	7 (1.3%)	0.363
Transplant	3 (0.6%)	3 (0.6%)	>0.999
HIV infection	2 (0.4%)	4 (0.8%)	0.687
Comorbidities (total number)			0.549
0	71 (13.5%)	78 (14.8%)	
1	157 (29.8%)	143 (27.2%)	
2	163 (31.0%)	173 (32.9%)	
3	87 (16.5%)	95 (18.1%)	

4	36 (6.8%)	31 (5.9%)	
>= 5	12 (2.3%)	6 (1.2%)	
Toxic habits			
Alcoholism	10 (1.9%)	10 (1.9%)	>0.999
Smoking	100 (19.0%)	115 (21.9%)	0.251

¹n (%); Median (IQR) ²Pearson's Chi-squared test; Wilcoxon rank sum test; Fisher's exact test.
COPD - Chronic obstructive pulmonary disease

The median duration of symptoms was 6 days (3-9 days) for both groups. The most predominant symptoms in disease presentation were dyspnea, fever and dry cough, being similar in both groups. Upon hospital presentation, patients with hypothyroidism had a lower frequency of respiratory rate over 24 breaths per minute (36.1% vs 42.0%; p=0.050), as well as lower proportion of mechanical ventilation (4.0% vs 7.4%; p=0.016) and of inotropics (24.3% vs 29.8%; p=0.044) requirement. The median peripheral oxygen saturation/fraction of inspired oxygen ratio (SF ratio) was slightly higher in patients with hypothyroidism than in the control group (428.6 vs. 423.8, p=0.034), as shown on Table 2.

Table 2- Clinical characteristics at hospital admission

	Hypothyroidism		Control patients		p-value ²
	N = 526 ¹	Non missing cases	N = 526 ¹	Non missing cases	
Symptoms					
Duration of symptoms (days)	6.0 (3.0, 9.0)	524	6.0 (3.0, 9.0)	524	0.635
Adynamic	138 (26.2%)	526	143 (27.2%)	526	0.728
Ageusia	25 (4.8%)	526	34 (6.5%)	526	0.228
Anosmia	44 (8.4%)	526	48 (9.1%)	526	0.662
Headache	95 (18.1%)	526	94 (17.9%)	526	0.936
Rhinorrhea	72 (13.7%)	526	79 (15.0%)	526	0.538
Diarrhea	84 (16.0%)	526	77 (14.6%)	526	0.549
Dyspnea	298 (56.7%)	526	316 (60.1%)	526	0.260
Fever	278 (52.9%)	526	247 (47.0%)	526	0.056

Hyporexia	71 (13.5%)	526	66 (12.5%)	526	0.647
Neurological manifestations	14 (2.7%)	526	21 (4.0%)	526	0.229
Myalgia	147 (27.9%)	526	130 (24.7%)	526	0.234
Nausea/vomiting	83 (15.8%)	526	69 (13.1%)	526	0.220
Productive cough	71 (13.5%)	526	79 (15.0%)	526	0.481
Dry cough	262 (49.8%)	526	268 (51.0%)	526	0.711
Clinical assessment					
GCS < 15	84 (16.0%)	526	83 (15.8%)	526	0.933
HR (bpm)	85.0 (74.0, 96.0)	505	87.0 (76.0, 98.0)	507	0.169
HR > 100 bpm	116 (22.1%)	526	131 (24.9%)	526	0.275
RR (bpm)	20.0 (18.0, 23.0)	443	20.0 (18.0, 24.0)	430	0.216
RR > 24 bpm	190 (36.1%)	526	221 (42.0%)	526	0.050
Sat O ₂ (%)	94.0 (91.0, 96.0)	513	94.0 (91.0, 97.0)	513	0.845
Sat O ₂ < 90%	98 (18.6%)	526	103 (19.6%)	526	0.695
Mechanical ventilation	21 (4.0%)	526	39 (7.4%)	524	0.016
Systolic blood pressure		526		526	0.693
SBP ≥ 90 mmHg	482 (91.6%)		464 (88.2%)		
SBP < 90 mmHg	25 (4.8%)		28 (5.3%)		
Inotropic use ²	19 (3.6%)		34 (6.5%)		
SF ratio ²	428.6 (339.3, 452.4)	507	423.8 (304.7, 452.4)	507	0.034

¹Median (IQR); n (%), ²Inotropic use at admission

SF ratio: peripheral capillary oxygen saturation/fraction of inspired oxygen (Spo₂/Fio₂ Ratio)

GCS: Glasgow coma score; HR: heart rate; RR: respiratory rate; Sat O₂: peripheral capillary oxygen saturation

Laboratory exams and biomarkers were similar between groups, except for D-dimer, which was lower in patients with hypothyroidism than the controls (Table 3).

Table 3- Findings of laboratory exams

	Hypothyroidism		Control patients		
	N = 526 ¹	Non missing cases	N = 526 ¹	Non missing cases	p-value ²
Hemogram					
Hemoglobin (g/L)	12.6 (11.6, 13.9)	515	12.9 (11.6, 13.8)	509	0.301
Leukocytes count (cels/mm ³)	6,785.0 (5,000.0, 9,302.5)	512	6,940.5 (5,200.0, 9,132.5)	510	0.317
Neutrophiles (cels/mm ³)	4,737.0 (3,310.5, 7,155.8)	498	5,204.0 (3,481.8, 7,281.2)	488	0.205
Lymphocytes (cels/mm ³)	1,100.0 (760.0, 1,503.5)	499	1,041.0 (710.0, 1,421.0)	489	0.136
Platelet count (10 ⁹ /L)	195.0 (151.0, 244.8)	508	196.3 (152.0, 261.0)	505	0.499
aPTT (secs/control)	1.0 (0.9, 1.2)	228	1.0 (0.9, 1.2)	265	0.396
Liver panel					
Albumin (g/dL)	3.4 (3.0, 3.7)	90	3.3 (3.0, 3.6)	104	0.283
Total bilirubin (mg/dL)	0.4 (0.3, 0.6)	253	0.4 (0.3, 0.6)	249	0.150
Direct Bilirubin (mg/dL)	0.2 (0.1, 0.3)	251	0.2 (0.1, 0.3)	249	0.013
AST (U/L)	37.4 (29.0, 55.0)	326	38.0 (28.0, 52.0)	334	0.750
ALT (U/L)	29.0 (20.0, 46.0)	323	28.0 (19.0, 44.3)	335	0.592
Electrolytes					
Calcium (mmol/L)	1.1 (1.1, 1.2)	138	1.1 (1.1, 1.2)	167	0.298

Potassium (mmol/L)	4.2 (3.8, 4.6)	476	4.1 (3.7, 4.5)	485	0.065
Sodium (mmol/L)	137.0 (134.0, 139.7)	474	137.7 (135.0, 140.0)	482	0.020
Others					
BNP (pg/mL)	78.0 (23.0, 230.5)	47	110.0 (32.8, 312.0)	48	0.218
Creatinine (mg/dL)	0.9 (0.8, 1.4)	493	0.9 (0.7, 1.2)	499	0.159
CPK (U/L)	81.5 (45.2, 145.8)	150	74.5 (47.0, 189.9)	149	0.668
D-dimer*	2.3 (1.2, 6.8)	301	2.9 (1.2, 23.9)	318	0.037
Ferritin (ng/mL)	80.1 (57.7, 142.0)	19	66.0 (42.0, 175.3)	17	0.447
Fibrinogen (g/L)	465.5 (334.5, 591.8)	40	451.0 (343.0, 553.0)	45	0.745
Lactate dehydrogenase	358.5 (255.2, 493.8)	282	363.0 (270.0, 504.0)	297	0.536
NT-proBNP (pg/mL)	310.0 (114.0, 785.7)	55	302.0 (89.3, 1,197.5)	70	0.895
C reactive protein (mg/L)	75.3 (32.1, 134.3)	466	74.8 (34.3, 143.3)	441	0.933
PTTa (secs/control)	1.0 (0.9, 1.2)	228	1.0 (0.9, 1.2)	265	0.396
INR	1.1 (1.0, 1.2)	291	1.1 (1.0, 1.2)	317	0.229
Troponin*	0.3 (0.1, 0.5)	171	0.3 (0.1, 0.5)	184	0.261
Lactate	1.4 (1.0, 1.9)	311	1.4 (1.1, 1.9)	321	0.427
Urea (mg/dL)	39.1 (28.0, 58.0)	492	38.0 (28.0, 55.8)	484	0.539

¹Median (IQR); n (%) ²Wilcoxon rank sum test; Fisher's exact test

aPTT: activated partial thromboplastin time; AST: aspartate transaminase; ALT: alanine aminotransferase; BNP B-type natriuretic peptide; CPK: creatine phosphokinase; NT-proBNP: N-terminal pro-brain natriuretic peptide; INR: international normalized ratio

* Times the reference value.

As for medications used during hospitalization, hypothyroidism patients had a lower frequency of inotropes requirement than the control group (24.3% vs. 29.8%, $p=0.044$). The other medications were similar between groups (Table S1).

With regards to patient outcomes, the median hospital length of stay (8 vs 9 days; $p=0.029$) and mechanical ventilation requirement (25.4% vs. 33.1%; $p=0.006$) were lower in patients with hypothyroidism than in controls. A trend of lower in-hospital mortality was seen in patients with hypothyroidism (22.1% vs. 27.0%; $p=0.062$). The other outcomes were similar between groups, as shown in Table 4.

Table 4- Patient outcomes

	Hypothyroidism N = 526¹	Control patients N = 526¹	p-value²
Hospital length of stay, days	8.0 (4.0, 14.0)	9.0 (5.0, 14.2)	0.029
ICU, days	197 (37.5%)	224 (42.6%)	0.089
Time of ICU admission	1.0 (0.0, 3.0)	1.0 (0.0, 2.0)	0.089
Days at ICU	8.0 (3.0, 15.0)	8.0 (4.0, 17.0)	0.293
Mechanical ventilation, number of patients	133 (25.4%)	172 (33.1%)	0.006
Dialysis	57 (10.8%)	63 (12.0%)	0.553
Sepsis	72 (13.7%)	90 (17.1%)	0.124
Disseminated Intravascular coagulation	0 (0.0%)	3 (0.6%)	0.249
Decompensated chronic heart failure	16 (3.0%)	25 (4.8%)	0.152
Acute heart failure	3 (0.6%)	6 (1.1%)	0.506
Nosocomial infection	48 (9.1%)	48 (9.1%)	>0.999
Miocardites	0 (0.0%)	3 (0.6%)	0.249
Hemorrhage	10 (1.9%)	9 (1.7%)	0.817
Vascular thrombosis	18 (3.4%)	22 (4.1%)	0.519

VTE	16 (3.0%)	21 (4.0%)	0.403
Arterial thrombosis	2 (0.4%)	1 (0.2%)	>0.999
In hospital mortality	116 (22.1%)	142 (27.0%)	0.062

¹Median (IQR); n (%) ²Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test
ICU (intensive care unit); VTE (venous thromboembolism)

DISCUSSION

In this multicenter cohort of in-hospital COVID-19 patients, those who had hypothyroidism had similar comorbidities, clinical manifestations and laboratory parameters when compared to the control group. Surprisingly, requirement for mechanical ventilation was remarkably lower in patients with underlying hypothyroidism, and there was a trend for lower hospital mortality when compared to controls, matched for age, sex, number of comorbidities and hospital.

Underlying individual comorbidities were similar between groups, except for chronic kidney disease and coronary artery disease. There has been a great interest in the relationship between thyroid dysfunction and kidney function in recent years.^{24,25} Thyroid hormones have shown to directly affect the kidneys, influencing renal growth and development, glomerular filtration rate, renal transport systems, as well as sodium and water homeostasis. An indirect effect through modifications in cardiac and vascular function and disruptions in the renin-angiotensin system is also believed to play an important role in reducing glomerular filtration rate through impaired renal autoregulation. At the same time, patients with autoimmune thyroid disorders are also at risk for immune-mediated glomerular diseases.²⁵

As for the higher prevalence of coronary artery disease, the association between hypothyroidism and increased cardiovascular risk is controversial when thyroid-stimulating hormone (TSH) is normal.²⁶ Nonetheless, it was demonstrated that patients with underlying hypothyroidism with a poor disease control have a worse lipidic profile and a higher prevalence of atherosclerosis, since thyroid hormones regulate lipid metabolism, especially TSH.^{27,28,29} At the same time, it is well established that a key-factor for adverse cardiovascular events prevention in patients with hypothyroidism is the achievement of symptom control, as well as levels of TSH and T4 within the reference values with the use of hormonal replacement therapy.³⁰ Another hypothesis to explain the higher frequency of

coronary artery disease is the higher prevalence of chronic kidney disease, which is associated with increased cardiovascular risk.

There was no difference in frequency and severity of COVID-19 symptoms between groups, including anosmia and ageusia. Despite the previous evidence of an effect of hypothyroidism at gustatory and olfactory perceptual pathways, including receptors, central olfactory and gustatory areas, and high order cognitive systems, previous cohorts studies did not observe a higher frequency of gustatory or olfactory COVID-19 symptoms in these patients. However, a case series has observed an independent association between hypothyroidism and a higher likelihood of persistent olfactory dysfunction among patients with COVID-19 (OR: 21.1; 95% CI: 2.0 to 219.4).³¹ Further studies are needed to investigate whether hypothyroidism is indeed associated with a higher risk of persistent symptoms.

Overall, laboratorial exams were similar between groups, except for D-dimer levels, which were slightly higher in the control group when compared to patients with hypothyroidism. However, the difference is not clinically relevant. These findings are different from a study from Wuhan, China, in the early phase of the pandemic, which observed that patients with thyroid dysfunction had persistently high levels of biomarkers for inflammatory response and cardiac injury. However, authors defined thyroid dysfunction by abnormal thyroid function tests results within three days from admission, and not previous underlying diseases.⁸

Current data shows that COVID-19 is associated with a broad spectrum of thyroid dysfunction, ranging from thyrotoxicosis to NTIS and hypothyroidism, that may worsen disease course and affect prognosis.^{32,33,34,35,36} This was observed even in mild to moderate COVID-19 cases, independently of SARS-CoV-2 viral load, age and inflammation and tissue injury markers.³⁷ The cytokine storm and the dysregulated inflammation are believed to affect the thyroid gland, through the proinflammatory cytokines, which resembles the immune activation that occurs in immune-mediated thyroid diseases, causing damage and compromising function.³² It is also possible that thyroid abnormalities are caused by a direct effect of the virus, leading to subacute thyroiditis, a self-limiting destructive thyroiditis, or affecting angiotensin-converting enzyme 2 (ACE2) receptors thyroid follicular cells, leading to a thyroid malfunction.³² Other contributing factors may be the oxidative stress due to augmented reactive oxygen species generation, which are associated with NTIS, and changes in the intracellular redox state, that may disrupt deiodinase function by independent mechanisms, which might include depletion of the- as yet unidentified- endogenous thiol

cofactor.³⁸ Nevertheless, there is no evidence that the administration of thyroid hormones improves prognosis in those patients. We might also wonder that, in some studies that observed a correlation between thyroid dysfunction and more severe COVID-19 presentation, the alterations in thyroid hormone levels were actually due to NTIS, as opposed to an underlying previous clinical thyroid disease.⁹ So, these results have to be carefully analysed.

Our findings suggest that underlying hypothyroidism does not lead to worse outcomes in patients with COVID-19. In fact, those patients presented indicators of better outcomes than patients without hypothyroidism. At hospital admission, respiratory rates over 24 breaths per minute were less frequent in hypothyroidism patients than in the control group (36.1% vs 42.0%; $p=0.050$). It is known that tachypnea is one of the alarming COVID-19 symptoms as it may be an indicator of COVID-19 pneumonia.³⁹ Despite the fact that SF ratio, a strong predictor of COVID-19 prognosis and mortality,^{4,40} was slightly higher in hypothyroidism patients, the difference was not clinically relevant (428.6 vs. 423.8, $p=0.034$).

The lower requirement of mechanical ventilation had not been observed previously, and it was quite unexpected. It is known that patients with decompensated hypothyroidism may have abnormalities in pulmonary function, muscle myopathy and neuropathy, with respiratory muscle weakness, but these abnormalities improve with treatment.^{41,42} In a previous propensity score matching analysis of patients from a New York health system, adjusted for age, sex, race, body mass index, smoking status, and number of comorbidities, hypothyroidism was not associated with an increased risk of mechanical ventilation (adjusted OR: 1.17 [95% CI: 0.81–1.69]) or death (adjusted OR: 1.07 [95% CI: 0.75–1.54]). However, this analysis was limited by the sample size of patients who were hospitalized, limited number of events, and fixed selection of three controls per case, which forces selection of controls.¹¹ The other previous cohort studies and case series were also limited by small sample sizes and lack of controls.^{8,9,11,13,31,43,44} In the present study, a caliper width of 0.17 was used for the matched analysis. It is considered conservative and restricts the selection of controls which are indeed similar to the cases, as recommended.⁴⁵ Due to a successful matched-analysis between samples, it is unlikely that age, sex or other underlying diseases have interfered with the results, although patients with hypothyroidism showed a higher prevalence for coronary artery disease and chronic kidney disease. Medications used during hospitalization were also similar in both groups, and, therefore, cannot explain the difference in prognosis as well.

Study limitations include its retrospective design, with data being collected by chart review only, and the fact that thyroid disease status was based on patients information given

at hospital admission, so it was not possible to know if the hypothyroidism was compensated or not. Nevertheless, to the best of our knowledge, the study has the largest sample of COVID-19 patients with hypothyroidism published so far. TSH and thyroid hormone (T4 and T3) levels were not evaluated during the time of hospitalization and time in the ICU, as this is not recommended during hospitalization due to Covid-19 or other acute diseases is by the health organizations, and it was not our aim to access the effects of NTIS. The assessment of thyroid hormone levels throughout the course of Covid-19 is still challenging due to the possibility of overdiagnosis due to abnormal hormone levels during acute systemic disease. It is important to emphasize that these hormonal changes are adaptive processes and cannot be defined as a disease itself.

CONCLUSION

In this multicenter cohort of Covid-19 in patients, those with underlying hypothyroidism, had similar comorbidities, clinical presentation and laboratory exams than the control group. It was found, nonetheless, that a lower proportion of patients with hypothyroidism required mechanical ventilation, and had a trend of lower in-hospital mortality. Therefore, hypothyroidism does not seem to be associated with a worse prognosis, and should not be considered among the comorbidities that indicate a risk factor for COVID-19 severity.

DECLARATIONS

Ethics approval

The study has been conducted by a protocol approved by the National Commission for Research Ethics¹⁵ (CAAE 30350820.5.1001.0008). Individual informed consent was waived due to the pandemic and to the fact that all data collected was unidentified, gathered through medical records.

Availability of data and materials

Data is available upon reasonable request.

Competing interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

This study was supported in part by Minas Gerais State Agency for Research and Development (*Fundação de Amparo à Pesquisa do Estado de Minas Gerais - FAPEMIG*) [grant number APQ-00208-20], National Institute of Science and Technology for Health Technology Assessment (*Instituto de Avaliação de Tecnologias em Saúde – IATS*)/ National Council for Scientific and Technological Development (*Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq*) [grant number 465518/2014-1 and 147122/2021-0].

DNP was funded by a research scholarship from IATS/CNPq [grant number 147122/2021-0].

Role of the funder/sponsor

The sponsors had no role in study design; data collection, management, analysis, and interpretation; writing the manuscript; and deciding to submit it for publication. DNP, LFGS, MMMG, MSM and MCP had full access to all the data in the study and had responsibility for the decision to submit for publication.

Authors contributions

Substantial contributions for the conception or design of the manuscript: MSM, DNP, LFGS and MMMG.

Substantial contributions for data acquisition, analysis or interpretation: all authors.

Manuscript formulation: MSM, DNP, LFGS, MMMG and MCP.

Critically revised the manuscript in relation to the important intellectual content: all authors.

Final version's approval: all authors

Agreed to be responsible for all aspects of the work, ensuring that issues related to precision of integrity in any of the work's parts will be properly investigated and solved: MSM and MCP.

Acknowledgments

We would like to thank the hospitals which are part of this collaboration, for supporting this project: Hospitais da Rede Mater Dei; Hospital das Clínicas da UFMG; Hospital de Clínicas de Porto Alegre; Hospital Santo Antônio; Hospital Eduardo de Menezes;

Hospital Tacchini; Hospital Márcio Cunha; Hospital Metropolitano Dr. Célio de Castro; Hospital Metropolitano Odilon Behrens; Hospital Risoleta Tolentino Neves; Hospital Santa Rosália; Hospital Santa Cruz; Hospital São João de Deus; Hospital Semper; Hospital Unimed-BH; Hospital Universitário Canoas; Hospital Universitário Santa Maria; Hospital Moinhos de Vento; Hospital Luxemburgo; Instituto Mario Penna; Hospital Nossa Senhora da Conceição; Hospital João XXIII; Hospital Júlia Kubitschek; Hospital Mãe de Deus; Hospital Regional do Oeste; Hospital das Clínicas da Faculdade de Medicina de Botucatu; Hospital Universitário Ciências Médicas; Hospital Bruno Born; Hospital SOS Córdio; Hospital São Lucas da PUCRS.

We also thank all the clinical staff at those hospitals, who cared for the patients, and all undergraduate students who helped with data collection.

Transparency declaration

The lead authors (DNP, MCP and MSM) affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned (and, if relevant, registered) have been explained.

LIST OF ABBREVIATIONS

COVID-19 - Coronavirus disease 19
 NTIS - Non-thyroidal illness syndrome
 T3 - Triiodothyronine
 T4 - Thyroxine
 TSH - Thyroid-stimulating hormone
 ICU - Intensive Care Unit
 REDCap - Research Data Capture
 COPD - Chronic obstructive pulmonary disease
 SF ratio - Peripheral oxygen saturation/fraction of inspired oxygen ratio
 GCS - Glasgow coma score
 HR - Heart rate
 RR - Respiratory rate
 Sat O₂ - Peripheral capillary oxygen saturation
 aPTT - Activated partial thromboplastin time
 AST - Aspartate transaminase

ALT - Alanine aminotransferase
 BNP - B-type natriuretic peptide
 CPK - Creatine phosphokinase
 NT-proBNP - N-terminal pro-brain natriuretic peptide
 INR - International normalized ratio
 VTE - Venous thromboembolism
 ACE 2 - Angiotensin-converting enzyme 2

REFERENCES

1. Gelfand MJ, Jackson JC, Pan X, Nau D, Pieper D, Denison E, et al. The relationship between cultural tightness-looseness and COVID-19 cases and deaths: a global analysis. *Lancet Planet Health*. 2021 Mar;5(3):e135-e144.
2. Centers for Disease Control and Prevention. People with Certain Medical Conditions. August 20th, 2021. September 4th, 2021. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html>
3. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, Hosein Z, Padda I, Mangat J, Altaf M. Comorbidity and its Impact on Patients with COVID-19. *SN Compr Clin Med*. 2020 Jun 25:1-8. doi: 10.1007/s42399-020-00363-4. Epub ahead of print. PMID: 32838147; PMCID: PMC7314621.
4. Marcolino MS, Pires MC, Ramos LEF, Silva RT, Oliveira LM, Carvalho RLR, Mourato RLS, Sánchez-Montalvá A, Raventós B, Anschau F, Chatkin JM, Nogueira MCA, Guimarães-Júnior MH, Vietta GG, Duani H, Ponce D, Ziegelmann PK, Castro LC, Ruschel KB, Cimini CCR, Francisco SC, Floriani MA, Nascimento GF, Farace BL, Monteiro LS, Souza-Silva MVR, Sales TLS, Martins KPMP, Borges do Nascimento IJ, Fereguetti TO, Ferrara DTMO, Botoni FA, Etges APBS, Schwarzbald AV, Maurílio AO, Scotton ALBA, Weber AP, Costa ASM, Glaeser AB, Madureira AAC, Bhering AR, de Castro BM, da Silva CTCA, Ramos CM, Gomes CD, de Carvalho CA, Silveira DV, Cezar E, Pereira EC, Kroger EMS, Vallt FB, Lucas FB, Aranha FG, Bartolazzi F, Crestani GP, Bastos GAN, Madeira GCC, Noal HC, Vianna HR, Guimarães HC, Gomes IM, Molina I, Batista JDL, de Alvarenga JC, Guimarães JDSS, de Moraes JDP, Rugolo JM, Pontes KCJR, Dos Santos KAM, de Oliveira LS, Pinheiro LS, Pacheco LS, Sousa LD, Couto LSF, Kopittke L, de Moura LCS, Santos LEA, Cabral MAS, Souza MD, Tofani MGT, Carneiro M, Ferreira MAP, Bicalho MAC, Lima MCPB, Godoy MF, Cardoso MMA, Figueiredo MP, Sampaio NCS, Rangel NL, Crespo NT, de Oliveira NR, Assaf PL, Martelli PJL, Almeida RSC, Martins RC, Lutkmeier R, Valacio RA, Finger RG, Cardoso RB, Pozza R, Campos RX, Menezes RM, de Abreu RM, Silva RF, Guimarães SMM, Araújo SF, Pereira SA, Oliveira TF, Kurtz T, de

- Oliveira TC, Araújo TSMA, Diniz THO, Dos Santos VB, Gomes VMR, do Vale VAL, Ramires YC, Boersma E, Polanczyk CA. ABC2-SPH risk score for in-hospital mortality in COVID-19 patients: development, external validation and comparison with other available scores. *Int J Infect Dis*. 2021 Sep;110:281-308. doi: 10.1016/j.ijid.2021.07.049. Epub 2021 Jul 24. PMID: 34311100; PMCID: PMC8302820.
5. Soeroto AY, Purwiga A, Emmy H Pranggono EHP, Roesli RMA. Asthma does not increase COVID-19 mortality and poor outcomes: A systematic review and meta-analysis. *Asian Pac J Allergy Immunol*. 2021 Apr 18. doi: 10.12932/AP-110920-0955. Epub ahead of print. PMID: 33865299.
6. Duntas LH, Jonklaas J. COVID-19 and Thyroid Diseases: A Bidirectional Impact. *J Endocr Soc*. 2021 Apr 27;5(8):bvab076. doi: 10.1210/jendso/bvab076. PMID: 34189381; PMCID: PMC8135350.
7. Leonidas H Duntas, Jacqueline Jonklaas, COVID-19 and Thyroid Diseases: A Bidirectional Impact, *Journal of the Endocrine Society*, Volume 5, Issue 8, August 2021, bvab076, <https://doi.org/10.1210/jendso/bvab076>
8. Zhang Y, Lin F, Tu W, Zhang J, Choudhry AA, Ahmed O, Cheng J, Cui Y, Liu B, Dai M, Chen L, Han D, Fan Y, Zeng Y, Li W, Li S, Chen X, Shen M, Pan P; medical team from Xiangya Hospital to support Hubei, China. Thyroid dysfunction may be associated with poor outcomes in patients with COVID-19. *Mol Cell Endocrinol*. 2021 Feb 5;521:111097. doi: 10.1016/j.mce.2020.111097. Epub 2020 Dec 2. PMID: 33278491; PMCID: PMC7709789.
9. Bakshi SS, Kalidoss VK. Is there an association between hypothyroidism and COVID 19? : A preliminary report. *Wien Klin Wochenschr*. 2021 Apr;133(7-8):414-415. doi: 10.1007/s00508-021-01813-2. Epub 2021 Feb 3. PMID: 33537842; PMCID: PMC7857644.
10. Martins JRM, Villagelin DGP, Carvalho GA, Vaisman F, Teixeira PFS, Scheffel RS, Sgarbi JA. Management of thyroid disorders during the COVID-19 outbreak: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM). *Arch Endocrinol Metab*. 2021 April 2. 65/3: 368-375. doi: 10.20945/2359-3997000000352
11. van Gerwen M, Alsen M, Little C, Barlow J, Naymagon L, Tremblay D, Sinclair CF, Genden E. Outcomes of Patients With Hypothyroidism and COVID-19: A Retrospective Cohort Study. *Front Endocrinol (Lausanne)*. 2020 Aug 18;11:565. doi: 10.3389/fendo.2020.00565. PMID: 33013686; PMCID: PMC7461836.
12. Shabrawishi M, Al-Gethamy MM, Naser AY, Ghazawi MA, Alsharif GF, Obaid EF, Melebari HA, Alamri DM, Brinji AS, Al Jehani FH, Almainani W, Ekram RA, Alkhatib KH, Alwafi H. Clinical, radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia. *PLoS One*. 2020 Aug 6;15(8):e0237130. doi: 10.1371/journal.pone.0237130. PMID: 32760107; PMCID: PMC7410246.

13. Daraei M, Hasibi M, Abdollahi H, Mirabdolhagh Hazaveh M, Zebardast J, Hajinoori M, Asadollahi-Amin A. Possible role of hypothyroidism in the prognosis of COVID-19. *Intern Med J*. 2020 Nov;50(11):1410-1412. doi: 10.1111/imj.15000. PMID: 33215834; PMCID: PMC7753499.
14. Fliers E, Bianco AC, Langouche L, Boelen A. Thyroid function in critically ill patients. *Lancet Diabetes Endocrinol*. 2015 Oct;3(10):816-25. doi: 10.1016/S2213-8587(15)00225-9. Epub 2015 Jun 10. PMID: 26071885; PMCID: PMC4979220.
15. Kim, S.-Y.; Yoo, D.-M.; Min, C.-Y.; Choi, H.-G. The Effects of Previous Thyroid Disease on the Susceptibility to, Morbidity of, and Mortality Due to COVID-19: A Nationwide Cohort Study in South Korea. *J. Clin. Med*. 2021, 10, 3522. <https://doi.org/10.3390/jcm10163522>
16. British Columbia Ministry of Health. Thyroid Function Testing in the Diagnosis and Monitoring of Thyroid Function Disorder. Guidelines and Protocol Advisory Committee. 2018 Oct 24. Available at: <https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/thyroid-function-testing.pdf>
17. Beltrão FEL, Beltrão DCA, Carvalhal G, Beltrão FEL, Brito AS, Capistrano KHR, Bastos IHA, Hecht F, Daltro CHC, Bianco AC, Gonçalves MCR, Ramos HE. Thyroid Hormone Levels During Hospital Admission Inform Disease Severity and Mortality in COVID-19 Patients. *Thyroid*. ahead of print <http://doi.org/10.1089/thy.2021.0225>
18. Gao W, Guo W, Guo Y, Shi M, Dong G, Wang G, Ge Q, Zhu J, Zhou X. Thyroid hormone concentrations in severely or critically ill patients with COVID-19. *J Endocrinol Invest*. 2021 May;44(5):1031-1040. doi: 10.1007/s40618-020-01460-w. Epub 2020 Nov 2. PMID: 33140379; PMCID: PMC7605732.
19. Marcolino MS, Ziegelmann PK, Souza-Silva MR, Nascimento IB, Oliveira LM, Monteiro LS, et al; Brazilian COVID-19 Registry Investigators. Clinical characteristics and outcomes of patients hospitalized with COVID-19 in Brazil: Results from the Brazilian COVID-19 registry. *Int J Infect Dis*. 2021 Jun;107:300-310.
20. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* 2007;335(7624):806-8.
21. Barreto PA, Braga AS, Andrade M. Evaluation of completeness of dengue records: exploratory study of compulsory notices. *Online Brazilian Journal of Nursing*. Sep, 2012.
22. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform* 2019;95:103208.
23. Marcolino MS, Ziegelmann PK, Souza-Silva MVR, Nascimento IJB, Oliveira LM, Monteiro LS, Sales TLS, Ruschel KB, Martins KPMP, Etges APBS,

- Molina I, Polanczyk CA; Brazilian COVID-19 Registry Investigators. Clinical characteristics and outcomes of patients hospitalized with COVID-19 in Brazil: Results from the Brazilian COVID-19 registry. *Int J Infect Dis.* 2021 Jun;107:300-310. doi: 10.1016/j.ijid.2021.01.019. Epub 2021 Jan 12. PMID: 33444752; PMCID: PMC7801187.
24. Iglesias P, Bajo MA, Selgas R, Díez JJ. Thyroid dysfunction and kidney disease: An update. *Rev Endocr Metab Disord.* 2017 Mar;18(1):131-144. doi: 10.1007/s11154-016-9395-7. PMID: 27864708.
25. Narasaki Y, Sohn P, Rhee CM. The Interplay Between Thyroid Dysfunction and Kidney Disease. *Semin Nephrol.* 2021 Mar;41(2):133-143. doi: 10.1016/j.semnephrol.2021.03.008. PMID: 34140092; PMCID: PMC8221115.
26. Decandia F. Risk factors for cardiovascular disease in subclinical hypothyroidism. *Ir J Med Sci.* 2018 Feb;187(1):39-43. doi: 10.1007/s11845-017-1617-9. Epub 2017 May 10. PMID: 28493136.
27. Kotwal A, Cortes T, Genere N, Hamidi O, Jasim S, Newman CB, Prokop LJ, Murad MH, Alahdab F. Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-analysis. *J Clin Endocrinol Metab.* 2020 Dec 1;105(12):dgaa672. doi: 10.1210/clinem/dgaa672. PMID: 32954428.
28. Tan M, Korkmaz H, Aydın H, Kumbul Doğuç D. FABP4 levels in hypothyroidism and its relationship with subclinical atherosclerosis. *Turk J Med Sci.* 2019 Oct 24;49(5):1490-1497. doi: 10.3906/sag-1904-41. PMID: 31651119; PMCID: PMC7018356.
29. Delitala AP, Fanciulli G, Maioli M, Delitala G. Subclinical hypothyroidism, lipid metabolism and cardiovascular disease. *Eur J Intern Med.* 2017 Mar;38:17-24. doi: 10.1016/j.ejim.2016.12.015. Epub 2016 Dec 28. PMID: 28040402.
30. Sue LY, Leung AM. Levothyroxine for the Treatment of Subclinical Hypothyroidism and Cardiovascular Disease. *Front Endocrinol (Lausanne).* 2020 Oct 21;11:591588. doi: 10.3389/fendo.2020.591588. PMID: 33193104; PMCID: PMC7609906.
31. Tsivgoulis G, Fragkou PC, Karofylakis E, Paneta M, Papathanasiou K, Palaodimou L, Psarros C, Papathanasiou M, Lachanis S, Sfrikakis PP, Tsiodras S. Hypothyroidism is associated with prolonged COVID-19-induced anosmia: a case-control study. *J Neurol Neurosurg Psychiatry.* 2021 Apr 20;jnnp-2021-326587. doi: 10.1136/jnnp-2021-326587. Epub ahead of print. PMID: 33879534.
32. Ruggeri RM, Campennì A, Deandreis D, Siracusa M, Tozzoli R, Petranović Ovcariček P, Giovanella L. SARS-COV-2-related immune-inflammatory thyroid disorders: facts and perspectives. *Expert Rev Clin Immunol.* 2021 Jul;17(7):737-759. doi: 10.1080/1744666X.2021.1932467. Epub 2021 Jun 2. PMID: 34015983; PMCID: PMC8182818.
33. Zou R, Wu C, Zhang S, Wang G, Zhang Q, Yu B, Wu Y, Dong H, Wu G, Wu S, Zhong Y. Euthyroid Sick Syndrome in Patients With COVID-19. *Front*

- Endocrinol (Lausanne). 2020 Oct 7;11:566439. doi: 10.3389/fendo.2020.566439. PMID: 33117282; PMCID: PMC7575767.
34. Malik J, Zaidi SMJ, Waqar AU, Khawaja H, Malik A, Ishaq U, Rana AS, Awan AH. Association of hypothyroidism with acute COVID-19: a systematic review. *Expert Rev Endocrinol Metab*. 2021 Aug 23;1-7. doi: 10.1080/17446651.2021.1968830. Epub ahead of print. PMID: 34424110.
35. Schwarz Y, Percik R, Oberman B, Yaffe D, Zimlichman E, Tirosh A. Sick Euthyroid Syndrome on Presentation of Patients With COVID-19: A Potential Marker for Disease Severity. *Endocr Pract*. 2021 Feb;27(2):101-109. doi: 10.1016/j.eprac.2021.01.001. Epub 2021 Jan 11. PMID: 33551316; PMCID: PMC7834506.
36. Baldelli R, Nicastrì E, Petrosillo N, Marchioni L, Gubbiotti A, Sperduti I, Di Giacinto P, Rizza L, Rota F, Franco M, Lania A, Aimaretti G, Ippolito G, Zuppi P. Thyroid dysfunction in COVID-19 patients. *J Endocrinol Invest*. 2021 Jun 8:1-5. doi: 10.1007/s40618-021-01599-0. Epub ahead of print. PMID: 34101132; PMCID: PMC8185485.
37. Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Fong CHY, Law CY, Leung EKH, To KKW, Tan KCB, Woo YC, Lam CW, Hung IFN, Lam KSL. Role of non-thyroidal illness syndrome in predicting adverse outcomes in COVID-19 patients predominantly of mild-to-moderate severity. *Clin Endocrinol (Oxf)*. 2021 Sep;95(3):469-477. doi: 10.1111/cen.14476. Epub 2021 Apr 12. PMID: 33813743; PMCID: PMC8250365.
38. Wajner SM, Maia AL. New Insights toward the Acute Non-Thyroidal Illness Syndrome. *Front Endocrinol (Lausanne)*. 2012 Jan 26;3:8. doi: 10.3389/fendo.2012.00008. PMID: 22654851; PMCID: PMC3356062.
39. Izquierdo JL, Ancochea J; Savana COVID-19 Research Group, Soriano JB. Clinical Characteristics and Prognostic Factors for Intensive Care Unit Admission of Patients With COVID-19: Retrospective Study Using Machine Learning and Natural Language Processing. *J Med Internet Res*. 2020 Oct 28;22(10):e21801. doi: 10.2196/21801. PMID: 33090964; PMCID: PMC7595750.
40. Mejía F, Medina C, Cornejo E, Morello E, Vásquez S, Alave J, Schwalb A, Málaga G. Oxygen saturation as a predictor of mortality in hospitalized adult patients with COVID-19 in a public hospital in Lima, Peru. *PLoS One*. 2020 Dec 28;15(12):e0244171. doi: 10.1371/journal.pone.0244171. PMID: 33370364; PMCID: PMC7769479.
41. Siafakas NM, Salesiotou V, Filaditaki V, Tzanakis N, Thalassinou N, Bouros D. Respiratory muscle strength in hypothyroidism. *Chest*. 1992 Jul;102(1):189-94. doi: 10.1378/chest.102.1.189. PMID: 1623751.
42. Laroche CM, Cairns T, Moxham J, Green M. Hypothyroidism presenting with respiratory muscle weakness. *Am Rev Respir Dis*. 1988 Aug;138(2):472-4. doi: 10.1164/ajrccm/138.2.472. PMID: 3195839.
43. Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Fong CHY, Law CY, Leung EKH, To KKW, Tan KCB, Woo YC, Lam CW, Hung IFN, Lam KSL.

Thyroid Dysfunction in Relation to Immune Profile, Disease Status, and Outcome in 191 Patients with COVID-19. J Clin Endocrinol Metab. 2021 Jan 23;106(2):e926-e935. doi: 10.1210/clinem/dgaa813. PMID: 33141191; PMCID: PMC7665541.

44. Allam MM, El-Zawawy HT, Ahmed SM, Aly Abdelhamid M. Thyroid disease and covid-19 infection: Case series. Clin Case Rep. 2021 Jun 17;9(6):e04225. doi: 10.1002/ccr3.4225. PMID: 34178336; PMCID: PMC8212015.
45. Austin, P. C. (2011). Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharmaceutical Statistics, 10, 150–161. doi:10.1002/pst.433

Supplementary

Table S1- Medications used during hospitalization

Medications	Hypothyroidism N = 526 ¹	Control Patients N = 526 ¹	p-value ²
Medications used for COVID-19 management*			
Azithromycin	393 (74.7%)	409 (77.8%)	>0.999
Chloroquine	6 (1.1%)	7 (1.3%)	>0.999
Hydroxychloroquine	41 (7.8%)	48 (9.1%)	0.085
Interferon	2 (0.4%)	0 (0.0%)	>0.999
Convalescent plasma	8 (1.5%)	5 (1.0%)	>0.999
Remdesivir	0 (0.0%)	1 (0.2%)	>0.999
Ritonavir/Lopinavir	1 (0.2%)	1 (0.2%)	>0.999
Clarithromycin	19 (3.6%)	24 (4.6%)	>0.999
Other medications used during hospitalization			
Antiarrhythmic	50 (9.5%)	44 (8.4%)	0.089
Antibiotics**	445 (84.6%)	463 (88.0%)	>0.999
Anticoagulation	469 (89.2%)	483 (91.8%)	>0.999
Prophylactic	393 (74.7%)	405 (77.0%)	>0.999
Therapeutic	79 (15.0%)	88 (16.7%)	>0.999
Antifungal	24 (4.6%)	31 (5.9%)	>0.999
Inotropes	128 (24.3%)	157 (29.8%)	0.044

Non-steroidal anti-inflammatory	87 (16.5%)	65 (12.4%)	0.144
Corticoids***	379 (72.1%)	363 (69.0%)	>0.999
Dexamethasone	326 (62.0%)	310 (58.9%)	>0.999
Other corticoids	88 (16.7%)	73 (13.9%)	>0.999
Statin	103 (19.6%)	73 (13.9%)	0.167

¹ n (%) ²Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test

*Sarilumab, Favipiravir, Immunoglobulin, Tocilizumab and Umifenovir were not used by any patients.

** Except for Azithromycin and Clarithromycin

*** Some patients used more than one type of corticoid